BRIEF-SUPERVALU says Rob Woseth to assume additional position of interim CFO
* Supervalu inc - rob woseth, executive vice president, chief strategy officer, will assume additional position of interim chief financial officer
Oct 18 Abbott Laboratories, which is in the process of buying St. Jude Medical Inc for $25 billion, said the companies would sell some of their medical devices to Japan-based Terumo Corp for about $1.12 billion.
Abbott said on Tuesday the deal is an important step toward completion of the St. Jude acquisition, which is scheduled to close by the year-end.
St. Jude has been under pressure after short-seller Muddy Waters and research firm MedSec Holdings alleged in August that the company's heart devices were riddled with defects that make them vulnerable to cyber hacks. St. Jude has denied the allegations and sued both companies.
The company said last week it would recall some of its 400,000 implanted heart devices due to risk of premature battery depletion, a condition linked to two deaths in Europe.
The all-cash transaction will include St. Jude Medical's Angio-Seal and Femoseal vascular closure products and Abbott's Vado Steerable Sheath, the companies said on Tuesday.
Abbott said it would retain the vascular closure products.
Abbott has been divesting to focus on its cardiovascular devices and diagnostics business, selling its medical optics division to Johnson & Johnson for $4.3 billion last month.
St. Jude's shares were up 1.62 percent at $78.92 in premarket trading, while Abbott shares were up 1 percent.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila)
* Epizyme expands clinical collaboration to study tazemetostat and tecentriq® combination in nsclc
* Wabco signs global long-term supply agreement with daimler trucks for additional automated manual transmission control technology